Daly AF, Rixhon M, Adam C, Dempegioti A, Tichomirowa MA & Beckers A. High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege, Belgium. Journal of Clinical Endocrinology and Metabolism 2006 91 4769-4775. (doi:10.1210/jc.2006-1668)
Gillam MP, Molitch ME, Lombardi G & Colao A. Advances in the treatment of prolactinomas. Endocrine Reviews 2006 27 485-534. (doi:10.1210/er.2005-9998)
Vergès B, Boureille F, Goudet P, Murat A, Beckers A, Sassolas G, Cougard P, Chambe B, Montvernay C & Calender A. Pituitary disease in MEN type 1 (MEN1): data from the France-Belgium MEN1 multicenter study. Journal of Clinical Endocrinology and Metabolism 2002 87 457-465. (doi:10.1210/jc.87.2.457)
Beckers A & Daly AF. The clinical, pathological, and genetic features of familial isolated pituitary adenomas. European Journal of Endocrinology 2007 157 371-382. (doi:10.1530/EJE-07-0348)
Jaffrain-Rea ML, Daly AF, Angelini M, Petrossians P, Bours V & Beckers A. Genetic susceptibility in pituitary adenomas: from pathogenesis to clinical implications. Expert Review of Endocrinology & Metabolism 2011 6 195-214. (doi:10.1586/eem.10.87)
Colao A & Savastano S. Medical treatment of prolactinomas. Nature Reviews. Endocrinology 2011 7 267-278. (doi:10.1038/nrendo.2011.37)
Verhelst J, Abs R, Maiter D, van den Bruel A, Vandeweghe M, Velkeniers B, Mockel J, Lamberigts G, Petrossians P, Coremans P, Mahler C, Stevenaert A, Verlooy J, Raftopoulos C & Beckers A. Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients. Journal of Clinical Endocrinology and Metabolism 1999 84 2518-2522. (doi:10.1210/jc.84.7.2518)
Di Sarno A, Landi ML, Cappabianca P, Di Salle F, Rossi FW, Pivonello R, Di Somma C, Faggiano A, Lombardi G & Colao A. Resistance to cabergoline as compared with bromocriptine in hyperprolactinemia: prevalence, clinical definition, and therapeutic strategy. Journal of Clinical Endocrinology and Metabolism 2001 86 5256-5261. (doi:10.1210/jc.86.11.5256)
Delgrange E, Daems T, Verhelst J, Abs R &Maiter D. Characterization of resistance to the prolactin-lowering effects of cabergoline in macroprolactinomas: a study in 122 patients. European Journal of Endocrinology 2009 160 747-752. (doi:10.1530/EJE-09-0012)
Webster J, Piscitelli G, Polli A, Ferrari CI, Ismail I & Scanlon MF. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline Comparative Study Group. New England Journal of Medicine 1994 331 904-909. (doi:10.1056/NEJM199410063311403)
Webster J, Piscitelli G, Polli A, D'Alberton A, Falsetti L, Ferrari C, Fioretti P, Giordano G, L'Hermite M, Ciccarelli E & European Multicentre Cabergoline Dose-finding Study Group. Dose-dependent suppression of serum prolactin by cabergoline in hyperprolactinaemia: a placebo controlled, double blind, multicentre study. European Multicentre Cabergoline Dose-finding Study Group. Clinical Endocrinology 1992 37 534-541. (doi:10.1111/j.1365-2265.1992. tb01485.x)
Molitch ME. The cabergoline-resistant prolactinoma patient: new challenges. Journal of Clinical Endocrinology and Metabolism 2008 93 4643-4645. (doi:10.1210/jc.2008-2244)
Delgrange E, Trouillas J, Maiter D, Donckier J & Tourniaire J. Sex-related difference in the growth of prolactinomas: a clinical and proliferation marker study. Journal of Clinical Endocrinology and Metabolism 1997 82 2102-2107. (doi:10.1210/jc.82.7.2102)
Daly AF, Tichomirowa MA, Petrossians P, Heliövaara E, Jaffrain-Rea ML, Barlier A, Naves LA, Ebeling T, Karhu A, Raappana A, Cazabat L, De Menis E, Montañana CF, Raverot G, Weil RJ, Sane T, Maiter D, Neggers S, Yaneva M, Tabarin A, Verrua E, Eloranta E, Murat A, Vierimaa O, Salmela PI, Emy P, Toledo RA, Sabaté MI, Villa C, Popelier M, Salvatori R, Jennings J, Ferrandez Longás A, Labarta Aizpún JI, Georgitsi M, Paschke R, Ronchi C, Valimaki M, Saloranta C, De Herder W, Cozzi R, Guitelman M, Magri F, Lagonigro MS, Halaby G, Corman V, Hagelstein MT, Vanbellinghen JF, Barra GB, Gimenez-Roqueplo AP, Cameron FJ, Borson-Chazot F, Holdaway I, Toledo SP, Stalla GK, Spada A, Zacharieva S, Bertherat J, Brue T, Bours V, Chanson P, Aaltonen LA & Beckers A. Clinical characteristics and therapeutic responses in patients with germ-line AIP mutations and pituitary adenomas: an International Collaborative Study. Journal of Clinical Endocrinology and Metabolism 2010 95 E373-E383. (doi:10.1210/jc.2009-2556)
Tichomirowa MA, Barlier A, Daly AF, Jaffrain-Rea ML, Ronchi C, Yaneva M, Urban JD, Petrossians P, Elenkova A, Tabarin A, Desailloud R, Maiter D, Schürmeyer T, Cozzi R, Theodoropoulou M, Sievers C, Bernabeu I, Naves LA, Chabre O, Fajardo-Montañana C, Hana V, Halaby G, Delemer B, Labarta Aizpún JI, Sonnet E, Ferrandez Longás A, Hagelstein MT, Caron P, Stalla GK, Bours V, Zacharieva S, Spada A, Brue T & Beckers A. High prevalence of AIP gene mutations following focused screening in young patients with sporadic pituitary macroadenomas. European Journal of Endocrinology 2011 165 509-515. (doi:10.1530/EJE-11-0304)
Naves LA, Jaffrain-Rea ML, Vêncio SA, Jacomini CZ, Casulari LA, Daly AF & Beckers A. Aggressive prolactinoma in a child related to germline mutation in the aryl hydrocarbon receptor interacting protein (AIP) gene. Arquivos Brasileiros de Endocrinologia e Metabologia 2010 54 761-767. (doi:10.1590/S0004-273020 10000800017)
Vasilev V, Daly AF, Vroonen L, Zacharieva S & Beckers A. Resistant prolactinomas. Journal of Endocrinological Investigation 2011 34 312-316.
Pellegrini I, Rasolonjanahary R, Gunz G, Bertrand P, Delivet S, Jedynak CP, Kordon C, Peillon F, Jaquet P & Enjalbert A. Resistance to bromocriptine in prolactinomas. Journal of Clinical Endocrinology and Metabolism 1989 69 500-509. (doi:10.1210/jcem-69-3-500)
Passos VQ, Fortes MA, Giannella-Neto D & Bronstein MD. Genes differentially expressed in prolactinomas responsive and resistant to dopamine agonists. Neuroendocrinology 2009 89 163-170. (doi:10.1159/000156116)
Caccavelli L, Feron F, Morange I, Rouer E, Benarous R, Dewailly D, Jaquet P, Kordon C & Enjalbert A. Decreased expression of the two D2 dopamine receptor isoforms in bromocriptineresistant prolactinomas. Neuroendocrinology 1994 60 314-322. (doi:10.1159/000126764)
Filopanti M, Barbieri AM, Angioni AR, Colao A, Gasco V, Grottoli S, Peri A, Baglioni S, Fustini MF, Pigliaru F, Monte PD, Borretta G, Ambrosi B, Jaffrain-Rea ML, Gasperi M, Brogioni S, Cannavò S, Mantovani G, Beck-Peccoz P, Lania A & Spada A. Dopamine D(2) receptor gene polymorphisms and response to cabergoline therapy in patients with prolactin-secreting pituitary adenomas. Pharmacogenomics Journal 2008 8 357-363. (doi:10.1038/tpj.2008.1)
Missale C, Losa M, Sigala S, Balsari A, Giovanelli M & Spano PF. Nerve growth factor controls proliferation and progression of human prolactinoma cell lines through an autocrine mechanism. Molecular Endocrinology 1996 10 272-285. (doi:10.1210/me.10. 3.272)
Gürlek A, Karavitaki N, Ansorge O & Wass JA. What are the markers of aggressiveness in prolactinomas? Changes in cell biology, extracellular matrix components, angiogenesis and genetics. European Journal of Endocrinology 2007 156 143-153. (doi:10.1530/eje.1.02339)
Wierinckx A, Auger C, Devauchelle P, Reynaud A, Chevallier P, Jan M, Perrin G, Fèvre-Montange M, Rey C, Figarella-Branger D, Raverot G, Belin MF, Lachuer J & Trouillas J. A diagnostic marker set for invasion, proliferation, and aggressiveness of prolactin pituitary tumors. Endocrine-Related Cancer 2007 14 887-900. (doi:10.1677/ERC-07-0062)
Raverot G, Wierinckx A, Dantony E, Auger C, Chapas G, Villeneuve L, Brue T, Figarella-Branger D, Roy P, Jouanneau E, Jan M, Lachuer J, Trouillas J & HYPOPRONOS . Prognostic factors in prolactin pituitary tumors: clinical, histological, and molecular data from a series of 94 patients with a long postoperative followup. Journal of Clinical Endocrinology and Metabolism 2010 95 1708-1716. (doi:10.1210/jc.2009-1191)
Sarkar DK. Genesis of prolactinomas: studies using estrogen-treated animals. Frontiers of Hormone Research 2006 35 32-49. (Pubitemid 44024240)
Jaffrain-Rea ML, Petrangeli E, Ortolani F, Fraioli B, Lise A, Esposito V, Spagnoli LG, Tamburrano G, Frati L & Gulino A. Cellular receptors for sex steroids in human pituitary adenomas. Journal of Endocrinology 1996 151 175-184. (doi:10.1677/joe.0. 1510175)
Wu ZB, Zheng WM, Su ZP, Chen Y, Wu JS,Wang CD, Lin C, Zeng YJ & Zhuge QC. Expression of D2RmRNA isoforms and ERmRNA isoforms in prolactinomas: correlation with the response to bromocriptine and with tumor biological behavior. Journal of Neuro-Oncology 2010 99 25-32. (doi:10.1007/s11060-009-0107- y)
Pinzone JJ, Katznelson L, Danila DC, Pauler DK, Miller CS & Klibanski A. Primary medical therapy of micro- and macroprolactinomas in men. Journal of Clinical Endocrinology and Metabolism 2000 85 3053-3057. (doi:10.1210/jc.85.9. 3053)
Shimon I, Benbassat C & Hadani M. Effectiveness of longterm cabergoline treatment for giant prolactinoma: study of 12 men. European Journal of Endocrinology 2007 156 225-231. (doi:10.1530/EJE-06-0646)
Daly AF, Vanbellinghen JF, Khoo SK, Jaffrain-Rea ML, Naves LA, Guitelman MA, Murat A, Emy P, Gimenez-Roqueplo AP, Tamburrano G, Raverot G, Barlier A, De Herder W, Penfornis A, Ciccarelli E, Estour B, Lecomte P, Gatta B, Chabre O, Sabaté MI, Bertagna X, Garcia Basavilbaso N, Stalldecker G, Colao A, Ferolla P, Wémeau JL, Caron P, Sadoul JL, Oneto A, Archambeaud F, Calender A, Sinilnikova O, Montañana CF, Cavagnini F, Hana V, Solano A, Delettieres D, Luccio-Camelo DC, Basso A, Rohmer V, Brue T, Bours V, Teh BT & Beckers A. Aryl hydrocarbon receptor-interacting protein genemutations in familial isolated pituitary adenomas: analysis in 73 families. Journal of Clinical Endocrinology and Metabolism 2007 92 1891-1896. (doi:10.1210/jc.2006- 2513)
Melmed S, Casanueva FF, Hoffman AR, Kleinberg DL, Montori VM, Schlechte J & Wass AH. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. Journal of Clinical Endocrinology and Metabolism 2011 96 273-288. (doi:10.1210/jc.2010-1692)
Ono M, Miki N, Kawamata T, Makino R, Amano K, Seki T, Kubo O, Hori T & Takano K. Prospective study of high-dose cabergoline treatment of prolactinomas in 150 patients. Journal of Clinical Endocrinology and Metabolism 2008 93 4721-4727. (doi:10.1210/jc.2007-2758)
Kars M, Pereira AM, Smit JW & Romijn JA. Long-term outcome of patients with macroprolactinomas initially treated with dopamine agonists. European Journal of Internal Medicine 2009 20 387-393. (doi:10.1016/j.ejim.2008. 11.012)
Hamilton DK, Vance ML, Boulos PT & Laws ER. Surgical outcome in hyporesponsive prolactinomas: analysis of patients with resistance or intolerance to dopamine agonists. Pituitary 2005 8 53-60. (doi:10.1007/s11102- 005-5086-1)
Petrossians P, Borges-Martins L, Espinoza C, Daly A, Betea D, Valdes-Socin H, Stevenaert A, Chanson P & Beckers A. Gross totalresection or debulking of pituitary adenomas improves hormonal control of acromegaly by somatostatin analogs. European Journal of Endocrinology 2005 152 61-66. (doi:10.1530/eje.1.01824)
Brada M & Jankowska P. Radiation therapy for pituitary adenomas. Endocrinology and Metabolism Clinics of North America 2008 37 263-275. (doi:10.1016/j.ecl.2007.10.005)
Kaltsas GA, Nomikos P, Kontogeorgos G, Buchfelder M & Grossman AB. Clinical review: diagnosis and management of pituitary carcinomas. Journal of Clinical Endocrinology and Metabolism 2005 90 3089-3099. (doi:10.1210/jc.2004- 2231)
Petrossians P, de Herder W, Kwekkeboom D, Lamberigts G, Stevenaert A & Beckers A. Malignant prolactinoma discovered by D2 receptor imaging. Journal of Clinical Endocrinology and Metabolism 2000 85 398-401. (doi:10.1210/jc.85.1.398)
Syro LV, Ortiz LD, Scheithauer BW, Lloyd R, Lau Q, Gonzalez R, Uribe H, Cusimano M, Kovacs K & Horvath E. Treatment of pituitary neoplasms with temozolomide: a review. Cancer 2011 117 454-462. (doi:10.1002/cncr.25413)
Raverot G, Sturm N, de Fraipont F, Muller M, Salenave S, Caron P, Chabre O, Chanson P, Cortet-Rudelli C, Assaker R, Dufour H, Gaillard S, François P, Jouanneau E, Passagia JG, Bernier M, Cornélius A, Figarella-Branger D, Trouillas J, Borson-Chazot F & Brue T. Temozolomide treatment in aggressive pituitary tumors and pituitarycarcinomas: a Frenchmulticenter experience. Journal of Clinical Endocrinology and Metabolism 2010 95 4592-4599. (doi:10.1210/jc.2010-0644)
Fusco A, Gunz G, Jaquet P, Dufour H, Germanetti AL, Culler MD, Barlier A & Saveanu A. Somatostatinergic ligands in dopamine-sensitive and -resistant prolactinomas. European Journal of Endocrinology 2008 158 595-603. (doi:10.1530/EJE-07-0806)
Hofland LJ, Hoek J, van Koetsveld PM, de Herder WW, Waaijers M, Sprij-Mooij D, Bruns C, Weckbecker G, Feelders R, Lely AJ, Beckers A & Lamberts SW. The novel somatostatin analog SOM230 is a potent inhibitor of hormone release by growth hormone- and prolactin-secreting pituitary adenomas in vitro. Journal of Clinical Endocrinology and Metabolism 2004 89 1577-1585. (doi:10.1210/jc.2003-031344)
Cristina C, García-Tornadú I, Díaz-Torga G, Rubinstein M, Low MJ & Becú-Villalobos D. Dopaminergic D2 receptor knockout mouse: an animal model of prolactinoma. Frontiers of Hormone Research 2006 35 50-63. (Pubitemid 44024241)
Roth BL. Drugs and valvular heart disease. New England Journal of Medicine 2007 356 6-9. (doi:10.1056/NEJMp068265)
Valassi E, Klibanski A & Biller BM. Clinical review: potential cardiac valve effects of dopamine agonists in hyperprolactinemia. Journal of Clinical Endocrinology and Metabolism 2010 95 1025-1033. (doi:10.1210/jc.2009- 2095)
